Trillium Therapeutics (NASDAQ:TRIL) Raised to “Buy” at BidaskClub

BidaskClub upgraded shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) from a hold rating to a buy rating in a research report report published on Tuesday, BidAskClub reports.

A number of other equities research analysts also recently commented on the company. ValuEngine raised Trillium Therapeutics from a hold rating to a buy rating in a report on Wednesday, August 19th. HC Wainwright raised Trillium Therapeutics from a neutral rating to a buy rating and set a $16.50 price target for the company in a research note on Thursday, September 10th. Zacks Investment Research raised Trillium Therapeutics from a strong sell rating to a hold rating in a research note on Tuesday, August 18th. Craig Hallum assumed coverage on Trillium Therapeutics in a research note on Monday, August 17th. They set a buy rating and a $15.00 price target for the company. Finally, JMP Securities lifted their price target on Trillium Therapeutics from $10.00 to $14.00 and gave the stock a market outperform rating in a research note on Wednesday, September 9th. They noted that the move was a valuation call. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $12.44.

Trillium Therapeutics stock opened at $13.62 on Tuesday. Trillium Therapeutics has a one year low of $0.24 and a one year high of $16.89. The business has a fifty day moving average of $11.04 and a two-hundred day moving average of $7.37. The company has a market cap of $1.18 billion, a P/E ratio of -5.54 and a beta of 2.23.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last released its earnings results on Wednesday, August 12th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.18). The business had revenue of $0.12 million during the quarter. On average, equities analysts anticipate that Trillium Therapeutics will post -1.02 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can acquired a new position in Trillium Therapeutics in the 2nd quarter valued at about $30,000. Rockefeller Capital Management L.P. purchased a new stake in Trillium Therapeutics in the 2nd quarter valued at about $40,000. Bamco Inc. NY purchased a new stake in Trillium Therapeutics in the 2nd quarter valued at about $52,000. Advisor Group Holdings Inc. grew its holdings in Trillium Therapeutics by 42.9% in the 2nd quarter. Advisor Group Holdings Inc. now owns 6,660 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 2,000 shares during the period. Finally, Steward Partners Investment Advisory LLC grew its holdings in Trillium Therapeutics by 260.0% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 7,200 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 5,200 shares during the period. 66.60% of the stock is owned by hedge funds and other institutional investors.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

See Also: What is the formula for the cash asset ratio?

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.